Increasing effectiveness of interferon-alpha for malignancies.
Alpha-interferons (IFN-alphas) have been shown to be effective agents in inducing the regression of various malignancies, including leukemias and lymphomas as well as solid tumors, and are the first human therapeutic proteins to result in increased survival in cancer patients. Based on their pleiotropic activities, IFNs have the potential for interacting synergistically with other anticancer agents. For example, preclinical in vitro and animal data suggest a synergistic antitumor interaction between IFN-alpha2 and the antiestrogens toremifene and tamoxifen. Further studies are required to elucidate the molecular basis for such synergistic interactions, particularly with respect to IFN-stimulated genes.
Lindner
D J
DJ
Department of Microbiology/Immunology, Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore 21201, USA.
Kalvakolanu
D V
DV
Borden
E C
EC
D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*; D011994:Recombinant Proteins
D007370:Interferon Type I; D011994:Recombinant Proteins